Login to Your Account

Dynavax Starting Phase III Trial Of Vaccine For Hepatitis B Virus

By Randall Osborne

Friday, June 24, 2005
Aiming to file a biologics license application in 2007, Dynavax Technologies Inc. began a pivotal Phase III trial to test its Toll-like receptor 9 hepatitis B vaccine against the efficacy of Engerix-B, GlaxoSmithKline plc's HBV vaccine, in older adults. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription